Accelerate Diagnostics Inc  

(Public, NASDAQ:AXDX)   Watch this stock  
Find more results for NYSEAMEX:AXK
22.05
-0.10 (-0.45%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 21.41 - 22.88
52 week 15.37 - 31.86
Open 21.99
Vol / Avg. 134,090.00/200,025.00
Mkt cap 984.69M
P/E     -
Div/yield     -
EPS -0.71
Shares 44.66M
Beta 0.71
Inst. own 31%
Mar 4, 2015
Accelerate Diagnostics Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -11094.94% -25354.92%
Operating margin -11111.39% -25833.61%
EBITD margin - -25103.28%
Return on average assets -48.51% -54.64%
Return on average equity -50.85% -57.55%
Employees 73 -
CDP Score - -

Address

3950 S. Country Club Road #470 Building 3-307
TUCSON, AZ 85714-2240
United States - Map
+1-303-8638088 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Accelerate Diagnostics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing instrumentation for the identification and antibiotic susceptibility testing of infectious pathogens. The Company�s BACcel platform utilizes a proprietary culture-free process with both genomic and phenotypic detection technologies. The Company�s BACcel system includes a fixed instrument and proprietary single-use test cassettes. Each cassette tests a single patient specimen and is then discarded. BACcel uses long-accepted bacteriological testing principles, but applies its technology to adapt them to analyze live bacteria extracted directly from a patient specimen. The Company�s other product includes OptiChem, which is used in micro arraying components. OptiChem offers noise rejection (non-specific binding by interfering substances) and capacity for target binding. OptiChem also offers the ability to apply micro-patterns, enabling analyzer designs.

Officers and directors

John Patience Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Lawrence Mehren President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Steve Reichling Chief Financial Officer
Age: 35
Bio & Compensation  - Reuters
Pete Bantock Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
Mark C. Miller Independent Director
Age: 52
Bio & Compensation  - Reuters
Jack W. Schuler Independent Director
Age: 74
Bio & Compensation  - Reuters
Matthew W. Strobeck Ph.D. Independent Director
Age: 41
Bio & Compensation  - Reuters
Frank J. M. ten Brink Independent Director
Age: 57
Bio & Compensation  - Reuters